This proposal focuses on the development and evaluating of human anti-HIV- 1 antibodies. The antibodies prepared in these studies are intended for therapeutic and prophylactic application in HIV-1 infection. Their development and characterization will further our understanding of the molecular requirements for HIV-1 entry and vaccine design. Large panels of antibodies reactive with the envelope glycoproteins of primary HIV-1 isolates representative of each clade will be prepared from combinatorial antibodies, and to define and discover novel neutralizing epitopes such as the chemokine receptor binding site which is formed when env binds CD4. Human antibodies will be evolved from antibodies selected from animals which have been immunized with defined antigens and antigen combinations using recently developed methodologies. The breadth and potency of the anti-HIV-1 activity of the selected antibodies will be defined, as well as the epitope to which they bind. Selection of peptides which mimic neutralizing epitopes as well as elicit these antibodies will be studies as a vaccine approach. Structural studies of antibodies in complex with env and peptides will further define structural requirements for vaccine design. We will address the therapeutic and prophylactic potential of potent and broadly reactive human antibodies in a small animal model, the hu-PBL-SCID mouse. We will study immunotoxin conjugates of antibodies in hopes of developing a curative strategy when combined with existing multi- drug therapies. Cell lines which produce large amounts of these human antibodies will be constructed with the goal of making these practical pharmaceuticals. Cumulatively, these studies will provide a more thorough understanding HIV-1 envelope interactions, requirements for the induction of effective humoral responses in vaccine design, and will result in new molecules for the treatment and prevention of HIV-1 infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI037470-05
Application #
2837454
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Program Officer
Sarver, Nava
Project Start
1994-12-01
Project End
2002-11-30
Budget Start
1998-12-01
Budget End
1999-11-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Popkov, Mikhail; Mage, Rose G; Alexander, Cornelius B et al. (2003) Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325:325-35
Berry, Jody D; Licea, Alexei; Popkov, Mikhail et al. (2003) Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics 22:23-31
Berry, Jody D; Rutherford, John; Silverman, Gregg J et al. (2003) Development of functional human monoclonal single-chain variable fragment antibody against HIV-1 from human cervical B cells. Hybrid Hybridomics 22:97-108
Goncalves, Joao; Silva, Frederico; Freitas-Vieira, Acilino et al. (2002) Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem 277:32036-45
Shabat, D; Lode, H N; Pertl, U et al. (2001) In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci U S A 98:7528-33
Andris-Widhopf, J; Rader, C; Steinberger, P et al. (2000) Methods for the generation of chicken monoclonal antibody fragments by phage display. J Immunol Methods 242:159-81
Rader, C; Cheresh, D A; Barbas 3rd, C F (1998) A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci U S A 95:8910-5
Bera, T K; Kennedy, P E; Berger, E A et al. (1998) Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 4:384-91
Zwick, M B; Bonnycastle, L L; Noren, K A et al. (1998) The maltose-binding protein as a scaffold for monovalent display of peptides derived from phage libraries. Anal Biochem 264:87-97
Gauduin, M C; Parren, P W; Weir, R et al. (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3:1389-93

Showing the most recent 10 out of 13 publications